The central finding
The financing strengthens the restart while introducing a near-term repayment timetable
The National Wealth Fund's August transaction brought together £36 million of equity and a £25 million core loan. A further £10 million accordion accounts for the balance of the £71 million headline, although that capacity remains uncommitted. Tungsten West subsequently disclosed that the £25 million loan had been fully drawn by approval of its annual accounts on 2 September 2026. The distinction matters for the restart: equity provides risk-bearing capital without a scheduled principal payment, whereas the loan places a repayment or refinancing obligation alongside the company's commissioning programme.
Management reports a fully funded pathway to production and has announced processing progress. Those developments materially improve the position described by the financing announcement, but the short loan tenor makes the timing of payable output, customer collections and replacement funding important to the next stage of commercial execution.
What the £71 million headline contains
£36m
Equity
Gross risk capital reported raised.
£25m
Core loan
Full draw disclosed by 2 September; repayment obligation.
£10m
Uncommitted accordion
Conditional additional borrowing capacity, not available cash.
£61 million gross equity and core-loan financing sits within the £71 million maximum. Amounts represent different instruments and cannot be read as current unrestricted cash.
Remaining expenditure and the tested sensitivities
Tungsten West's October guidance placed remaining project expenditure at approximately £40–45 million, excluding operating costs. The research uses £42.5 million as a midpoint reference and tests an illustrative £5.75 million increment combining the upper end of the capital range, a company-described delay sensitivity and a separately labeled one-year interest-rate proxy. It is a scenario for analyzing exposure, not a prediction of additional spending.
A different model exercise returns to the company's original August funding plan. Deferring all £15 million of anticipated receipts while holding other items fixed produces approximately £2 million negative cash using published aggregate totals, or £1 million using separately rounded details. These results illuminate the plan's dependence on receipts at that historical point; they do not establish a cash shortage at the November research cutoff. The October stress and August counterfactual have different bases and are not added together.
What matters next
The September Elmet offtake agreement gives Hemerdon a documented route to market, while processing and commissioning updates indicate progress toward producing saleable tungsten. Financial performance will ultimately depend on the conversion of those operating milestones into accepted deliveries and collected receipts. For creditors, the decisive information is the executed loan timetable and a reconciled cash and debt schedule; for equity investors, the same operational evidence informs the ability to fund the remaining ramp without unexpected financing costs or dilution.
The full memo, executive deck and accompanying model examine those relationships in greater depth. The analysis does not estimate current unrestricted cash, a complete funding gap, project valuation, covenant headroom or repayment sufficiency because the public disclosures reviewed do not support those calculations.